{"id":69104,"date":"2026-06-30T14:55:31","date_gmt":"2026-06-30T06:55:31","guid":{"rendered":"https:\/\/flcube.com\/?p=69104"},"modified":"2026-06-30T14:55:31","modified_gmt":"2026-06-30T06:55:31","slug":"qyuns-therapeutics-to-acquire-remaining-34-stake-in-cmc-subsidiary-cellularforce-for-rmb-86m-full-ownership-secures-nda-pathway-for-il-17a-and-il-4r%ce%b1-antibody-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69104","title":{"rendered":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Qyuns Therapeutics Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) announced that its wholly-owned subsidiary <strong>Qyuns Safe Biology Medicine Co., Ltd.<\/strong> has entered into an equity transfer agreement to acquire an <strong>approximately 34.0001% equity stake<\/strong> in <strong>Cellularforce<\/strong> from <strong>Taizhou Huacheng Medical Investment Group Co., Ltd.<\/strong> for <strong>RMB 86.02 million<\/strong> ($11.9 million), achieving <strong>100% indirect ownership<\/strong> of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Qyuns Safe Biology Medicine Co., Ltd. (wholly-owned subsidiary of Qyuns Therapeutics)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Cellularforce (CMC-focused subsidiary)<\/td><\/tr><tr><td><strong>Stake Acquired<\/strong><\/td><td>34.0001% equity interest<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>RMB 86.02 million (approximately $11.9 million)<\/td><\/tr><tr><td><strong>Post-Transaction Ownership<\/strong><\/td><td>100% indirect ownership through Safe Biology Medicine<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>June 26, 2026<\/td><\/tr><tr><td><strong>Strategic Purpose<\/strong><\/td><td>Facilitate NDA submissions for core pipeline products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-subsidiary-profile-cellularforce\" class=\"wp-block-heading\">Subsidiary Profile: Cellularforce<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Function<\/strong>: CMC (Chemistry, Manufacturing, and Controls) operations<\/li>\n\n\n\n<li><strong>Core Capabilities<\/strong>:<\/li>\n\n\n\n<li>Cell line development<\/li>\n\n\n\n<li>Process development<\/li>\n\n\n\n<li>Formulation development<\/li>\n\n\n\n<li>Analytical method development<\/li>\n\n\n\n<li>Quality control (QC) and quality assurance (QA)<\/li>\n\n\n\n<li>Pilot production and commercial manufacturing<\/li>\n\n\n\n<li><strong>Strategic Role<\/strong>: Central manufacturing and development platform for Qyuns&#8217; antibody pipeline<\/li>\n\n\n\n<li><strong>Integration Status<\/strong>: Will become fully integrated CMC arm under 100% Qyuns ownership<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Cellularforce serves as the backbone of Qyuns&#8217; biologics development infrastructure, providing end-to-end CMC capabilities essential for regulatory compliance and commercial-scale manufacturing of monoclonal antibodies.<\/p>\n\n\n\n<h2 id=\"h-pipeline-impact-amp-regulatory-strategy\" class=\"wp-block-heading\">Pipeline Impact &amp; Regulatory Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Core Product<\/th><th>Target<\/th><th>Development Stage<\/th><th>CMC Dependency<\/th><\/tr><\/thead><tbody><tr><td><strong>QX002N<\/strong><\/td><td>Anti-IL-17A monoclonal antibody<\/td><td>Pre-NDA<\/td><td>High &#8211; requires robust CMC package<\/td><\/tr><tr><td><strong>Oturkibart (QX005N)<\/strong><\/td><td>Anti-IL-4R\u03b1 monoclonal antibody<\/td><td>Pre-NDA<\/td><td>High &#8211; requires robust CMC package<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition directly supports Qyuns&#8217; near-term regulatory objectives by ensuring complete control over the CMC components of New Drug Applications (NDAs) for both lead candidates. Full ownership eliminates potential coordination challenges with minority stakeholders during the critical NDA preparation and regulatory review phases.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-context\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Driver<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Control<\/strong><\/td><td>Complete oversight of CMC data generation and submission processes<\/td><\/tr><tr><td><strong>Operational Efficiency<\/strong><\/td><td>Streamlined decision-making for manufacturing scale-up and process optimization<\/td><\/tr><tr><td><strong>Intellectual Property Security<\/strong><\/td><td>Enhanced protection of proprietary manufacturing processes and analytical methods<\/td><\/tr><tr><td><strong>Commercial Readiness<\/strong><\/td><td>Accelerated pathway to commercial manufacturing upon NDA approval<\/td><\/tr><tr><td><strong>Investor Confidence<\/strong><\/td><td>Demonstrates commitment to de-risking regulatory pathway for core assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">China&#8217;s biologics market continues rapid growth, with monoclonal antibodies representing a significant segment. The IL-17A and IL-4R\u03b1 targets address substantial markets in autoimmune diseases, including psoriasis, atopic dermatitis, and asthma, with combined global market potential exceeding $20 billion annually.<\/p>\n\n\n\n<h2 id=\"h-financial-structure-amp-integration-benefits\" class=\"wp-block-heading\">Financial Structure &amp; Integration Benefits<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The RMB 86.02 million consideration represents a strategic investment that secures full control over critical manufacturing infrastructure. The transaction is expected to be immediately accretive by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Eliminating minority interest expenses<\/li>\n\n\n\n<li>Enabling optimal resource allocation across the CMC platform<\/li>\n\n\n\n<li>Accelerating NDA timelines through unified operational control<\/li>\n\n\n\n<li>Reducing regulatory risk through consistent quality systems<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, regulatory submissions, and commercial prospects of Qyuns&#8217; pipeline. Actual results may differ due to risks including regulatory decisions, clinical outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062602696_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026062602696_c.\"><\/object><a id=\"wp-block-file--media-e17f95ff-5d41-4bb7-b53d-837a4a1a05ef\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062602696_c.pdf\">2026062602696_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062602696_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e17f95ff-5d41-4bb7-b53d-837a4a1a05ef\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1239,4827,495],"class_list":["post-69104","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2509","tag-qyuns-safe-biology-medicine","tag-qyuns-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69104\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline\" \/>\n<meta property=\"og:description\" content=\"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69104\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T06:55:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline\",\"datePublished\":\"2026-06-30T06:55:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104\"},\"wordCount\":492,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2509\",\"Qyuns Safe Biology Medicine\",\"QYuns Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69104#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69104\",\"name\":\"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-30T06:55:31+00:00\",\"description\":\"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69104\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69104#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69104","og_locale":"en_US","og_type":"article","og_title":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline","og_description":"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.","og_url":"https:\/\/flcube.com\/?p=69104","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T06:55:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69104#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69104"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline","datePublished":"2026-06-30T06:55:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69104"},"wordCount":492,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2509","Qyuns Safe Biology Medicine","QYuns Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69104#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69104","url":"https:\/\/flcube.com\/?p=69104","name":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-30T06:55:31+00:00","description":"Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69104#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69104"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69104#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M \u2013 Full Ownership Secures NDA Pathway for IL-17A and IL-4R\u03b1 Antibody Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69104"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69104\/revisions"}],"predecessor-version":[{"id":69106,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69104\/revisions\/69106"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}